Bellicum Pharmaceuticals to Present at the Jefferies 2018 London Healthcare Conference
November 07 2018 - 7:00AM
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in
developing novel, controllable cellular immunotherapies for cancers
and orphan inherited blood disorders, today announced
that Rick Fair, President and CEO, is scheduled
to present a corporate overview at the Jefferies
2018 London Healthcare Conference on Wednesday, November
14 at 5:20 p.m. GMT in London, UK.
A live webcast of the presentation may be accessed from
the News & Events section of the Bellicum website. An
archived version of the webcast will be available for replay for at
least two weeks following the event.
About Bellicum Pharmaceuticals Bellicum is
a clinical stage biopharmaceutical company striving to deliver
cures through controllable cell therapies. The Company’s
next-generation product candidates are differentiated by powerful
cell signaling technologies designed to produce more effective
CAR-T, TCR and allogeneic T cell therapies. Its lead product
candidate, rivo-celTM, is an allogeneic polyclonal T cell therapy
that has shown promising clinical trial results in reducing
leukemia relapse after a stem cell transplant. Bellicum’s lead
GoCAR-T® candidate, BPX-601, is designed to be a more efficacious
CAR-T cell product capable of overriding key immune inhibitory
mechanisms. More information can be found
at www.bellicum.com.
Source: Bellicum Pharmaceuticals
Investors:
Solebury Trout
Chad Rubin
646-378-2947
crubin@soleburytrout.com
Media:
Solebury Trout
Brad Miles
646-513-3125
bmiles@soleburytrout.com
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Apr 2023 to Apr 2024